Your session is about to expire
← Back to Search
Taxane Chemotherapy
1 for Prostate Cancer
Phase 1 & 2
Waitlist Available
Led By Michael J Morris, M.D.
Research Sponsored by Cytogen Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
The purpose of this study is to investigate the safety, tolerability and anti-tumor effects of treatment with samarium Sm-153 lexidronam in combination with docetaxel in patients with castrate metastatic prostate cancer.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
is safety and tolerability of the combination treatment
Secondary outcome measures
Tumor response will be assessed when possible using RECIST criteria.
Trial Design
1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Cytogen CorporationLead Sponsor
5 Previous Clinical Trials
115 Total Patients Enrolled
2 Trials studying Prostate Cancer
45 Patients Enrolled for Prostate Cancer
Michael J Morris, M.D.Principal InvestigatorMemorial Sloan Kettering Cancer Center
1 Previous Clinical Trials
30 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger